Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

586 articles

Showing 1–2 of 2 articles · Keyword: Adverse reactions Clear keyword

International journal of pharmaceutics2026ResearchNon-viral Gene DeliveryDrug Delivery

1. Enhancing mRNA-lipid nanoparticle vaccine-induced T cell responses by simple supplementation with class B CpG oligodeoxynucleotides

Hirata H, Abe Y, Itoh Y, Hirai T, Yoshioka Y

mRNA-lipid nanoparticle (LNP) vaccines can elicit robust T cell responses; however, these responses remain insufficient, particularly in the context of cancer vaccine therapy. Although several types of adjuvants reportedly enhance T cell responses induced by mRNA-LNP vaccines, few comprehensive side-by-side…

Read the article
Journal of controlled release : official journal of the Controlled Release Society2026ResearchNon-viral Gene DeliveryDrug Delivery

2. Rationally designed negatively charged lipid nanoparticles reduce systemic reactogenicity of mRNA vaccines while preserving immunogenicity

Karaki T, Inoue W, Gis T, Shichinohe S, Watanabe T, Hirai T, Et Al.

Messenger RNA (mRNA) vaccines have emerged as versatile platforms for the prevention of infectious diseases and therapeutic cancer vaccination. However, strong reactogenicity remains a key challenge, with severe adverse events such as myocarditis. These concerns may limit the applications of mRNA vaccines. As lipid…

Read the article
Articles | Brilliant Blue Biosciences